Chen SC et al. |
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29043411
|
Li C et al. |
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane. |
2017 |
Cancer Chemother. Pharmacol. |
pmid:29022084
|
Douros J and Suffness M |
New natural products of interest under development at the National Cancer Institute. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:86390
|
Li C et al. |
Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. |
2016 |
Cancer Chemother. Pharmacol. |
pmid:27423671
|
Rodon J et al. |
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. |
2008 |
Cancer Chemother. Pharmacol. |
pmid:18301896
|
Girish S et al. |
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. |
2012 |
Cancer Chemother. Pharmacol. |
pmid:22271209
|
Carter SK |
New drugs under clinical evaluation in the United States. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:155503
|
Blum RH et al. |
A therapeutic trial of maytansine. |
1978 |
Cancer Clin Trials |
pmid:757139
|
|
Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. |
2016 |
Cancer Discov |
pmid:26701087
|
|
T-DM1 Extends Survival in HER2+ Breast Cancer. |
2016 |
Cancer Discov |
pmid:26676162
|